怀孕期糖尿病诊断后的2型糖尿病风险沟通:一种定性研究
Molly Caba1, Alison Northern2, Amar Virdee2
1Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK.
被诊断为妊娠期糖尿病 (GDM) 的妇女往往只能获得关于她们患2型糖尿病 (T2DM) 风险增加的信息. 改善沟通和支持对女性至关重要.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 孕期糖尿病 (GDM) 显著提高了女性一生患2型糖尿病 (T2DM) 的风险.
- 有效地沟通T2DM风险对于影响女性的健康行为至关重要.
- 了解女性对T2DM风险沟通的看法对于改善产后护理至关重要.
研究的目的:
- 探索女性与2型糖尿病风险沟通的经验,并在怀孕期糖尿病诊断后提供支持.
- 识别医疗保健专业沟通中关于GDM妇女长期T2DM风险的差距.
主要方法:
- 定性研究采用半结构面试对10名先前被诊断患有GDM的女性进行.
- 使用反射主题分析分析采访成绩单的分析.
主要成果:
- 妇女通常在GDM期间和之后报告T2DM风险沟通很少,导致被遗忘的感觉和缺乏意识.
- 沟通不足导致了对T2DM,其影响和必要的预防措施的知识差距和误解.
- 参与者提出了改进建议,包括团体教育,可访问的资源,个性化信息和一致的风险沟通.
结论:
- 目前关于T2DM风险和GDM后支持的沟通缺陷使女性感到支持不足.
- 建议改善医疗保健沟通和支持系统,以更好地管理有GDM史的女性T2DM风险.
更多相关视频
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
14:43A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Oral Hypoglycemic Agents: Biguanides and Glitazones
